Automate Your Wheel Strategy on IMA
With Tiblio's Option Bot, you can configure your own wheel strategy including IMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMA
- Rev/Share 0.0
- Book/Share 2.4018
- PB 3.5848
- Debt/Equity 0.049
- CurrentRatio 13.519
- ROIC -0.3602
- MktCap 96274230.0
- FreeCF/Share -0.6047
- PFCF -3.2991
- PE -13.5149
- Debt/Assets 0.045
- DivYield 0
- ROE -0.2488
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMA | Leerink Partners | -- | Outperform | -- | $30 | Oct. 24, 2025 |
News
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
IMA
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About ImageneBio Inc (IMA)
- IPO Date 1998-02-27
- Website https://www.inmagenebio.com
- Industry Biotechnology
- CEO Kristin Yarema
- Employees 10
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis